X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1944) 1944
Publication (208) 208
Book Review (19) 19
Conference Proceeding (3) 3
Book Chapter (2) 2
Newsletter (2) 2
Book / eBook (1) 1
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1057) 1057
animals (969) 969
index medicus (965) 965
male (588) 588
female (499) 499
nanoparticles (487) 487
ferric compounds - pharmacokinetics (455) 455
ferric compounds - chemistry (437) 437
ferric oxide (401) 401
iron compounds (400) 400
mice (393) 393
iron (388) 388
rats (381) 381
magnetic resonance imaging (332) 332
pharmacology & pharmacy (326) 326
adult (252) 252
ferric compounds - administration & dosage (242) 242
nanoscience & nanotechnology (238) 238
iron - pharmacokinetics (233) 233
biological availability (228) 228
ferrous compounds - pharmacokinetics (222) 222
cancer (219) 219
magnetic resonance imaging - methods (215) 215
chemistry, multidisciplinary (191) 191
tissue distribution (190) 190
absorption (178) 178
particle size (177) 177
pharmacokinetics (176) 176
cell line, tumor (169) 169
drug delivery systems (167) 167
middle aged (165) 165
radiology, nuclear medicine & medical imaging (165) 165
magnetic nanoparticles (164) 164
nanoparticles - chemistry (163) 163
therapy (159) 159
nutrition & dietetics (158) 158
biochemistry & molecular biology (156) 156
contrast media (155) 155
mri (154) 154
article (152) 152
in-vivo (152) 152
anemia (150) 150
magnetite nanoparticles - chemistry (150) 150
iron oxides (147) 147
contrast agents (145) 145
cells (140) 140
drug-delivery (140) 140
research (140) 140
bioavailability (138) 138
health aspects (136) 136
drugs (135) 135
ferrous compounds - administration & dosage (135) 135
contrast media - pharmacokinetics (129) 129
ferric compounds (124) 124
materials science, multidisciplinary (119) 119
toxicity (118) 118
administration, oral (116) 116
ferric compounds - pharmacology (116) 116
iron - metabolism (116) 116
nanotechnology (114) 114
tumors (113) 113
analysis (112) 112
iron-oxide nanoparticles (112) 112
magnetics (112) 112
oxidative stress (112) 112
rats, sprague-dawley (110) 110
ferric compounds - therapeutic use (109) 109
liver - metabolism (109) 109
medicine (109) 109
contrast media - chemistry (107) 107
eisenoxid (106) 106
time factors (106) 106
anemia, iron-deficiency - drug therapy (105) 105
in-vitro (104) 104
liver (104) 104
iron - blood (103) 103
nanopartikel (103) 103
ferric compounds - metabolism (102) 102
intestinal absorption (98) 98
iron oxide nanoparticles (98) 98
vehicles (96) 96
dose-response relationship, drug (95) 95
delivery (93) 93
ferric compounds - toxicity (92) 92
materials science, biomaterials (92) 92
particles (89) 89
aged (88) 88
kinetics (88) 88
ferrous compounds - pharmacology (87) 87
biodistribution (86) 86
magnetite nanoparticles (85) 85
contrast agent (84) 84
ferrous compounds - chemistry (83) 83
food, fortified (82) 82
medicine, research & experimental (82) 82
nuclear magnetic resonance--nmr (81) 81
inflammation (80) 80
metabolism (79) 79
rats, wistar (79) 79
toxicology (79) 79
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1912) 1912
Japanese (13) 13
German (10) 10
Russian (9) 9
Chinese (6) 6
Spanish (4) 4
Italian (3) 3
French (2) 2
Polish (2) 2
Bulgarian (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chemical Society Reviews, ISSN 0306-0012, 2015, Volume 44, Issue 23, pp. 8576 - 8607
Iron oxide nanoparticles (IONPs) have been extensively used during the last two decades, either as effective bio-imaging contrast agents or as carriers of... 
Journal Article
Materials Science & Engineering C, ISSN 0928-4931, 02/2017, Volume 71, pp. 504 - 511
Magnetic nanoparticles (MNPs) are the major class of nanoparticles (NPs) with specific functional properties that make them good candidates for biomedical... 
Manganese magnetic nanoparticles | PEG | pH- sensitive | Chitosan | Methotrexate | Co-precipitation | IRON-OXIDE NANOPARTICLES | SYSTEM | VITRO | MATERIALS SCIENCE, BIOMATERIALS | TARGETED DRUG-DELIVERY | SIZE | NANO-MAGNETIC PARTICLES | Manganese magnetic nanopartides | pH-sensitive | THERAPY | IN-VIVO | Manganese Compounds - pharmacokinetics | Methotrexate - pharmacology | Coated Materials, Biocompatible - pharmacokinetics | Nanoparticles - chemistry | Humans | Methotrexate - pharmacokinetics | Coated Materials, Biocompatible - pharmacology | Coated Materials, Biocompatible - chemistry | Polyethylene Glycols - pharmacokinetics | Delayed-Action Preparations - chemistry | Ferric Compounds - chemistry | Ferric Compounds - pharmacology | Polyethylene Glycols - chemistry | Chitosan - chemistry | Ferric Compounds - pharmacokinetics | MCF-7 Cells | Chitosan - pharmacokinetics | Delayed-Action Preparations - pharmacology | Delayed-Action Preparations - pharmacokinetics | Chitosan - pharmacology | Manganese Compounds - pharmacology | Manganese Compounds - chemistry | Methotrexate - chemistry | Polyethylene Glycols - pharmacology | Drugs | Drug delivery systems | Magnetization | Polyols | Vehicles | Nanoparticles | Iron compounds | Polyethylene glycol | Analysis | Precipitation (Meteorology) | Magnetic fields | Hydrogen-ion concentration | Magnetic properties | Fourier transforms | Tumors
Journal Article
Current Drug Metabolism, ISSN 1389-2002, 06/2014, Volume 15, Issue 10, pp. 953 - 965
Sucroferric oxyhydroxide (VELPHORO (R)) is a polynuclear iron-based phosphate binder recently approved for the treatment of hyperphosphataemia in patients with... 
Hyperphosphataemia | Phosphate | Phosphate binder | Dialysis | Preclinical | Chronic kidney disease (CKD) | Sucroferric oxyhydroxide | dialysis | IRON-OVERLOAD | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHOSPHATE BINDER PA21 | VASCULAR CALCIFICATION | phosphate | phosphate binder | CALCIUM-CARBONATE | preclinical | hyperphosphataemia | HEMODIALYSIS-PATIENTS | CARDIOVASCULAR-DISEASE | PARATHYROID-HORMONE | MINERAL METABOLISM | PHARMACOLOGY & PHARMACY | CHRONIC KIDNEY-DISEASE | sucroferric oxyhydroxide | CHRONIC-RENAL-FAILURE | Chelating Agents - administration & dosage | Humans | Uremia - physiopathology | Ferric Compounds - administration & dosage | Renal Insufficiency, Chronic - complications | Sucrose - pharmacokinetics | Hyperphosphatemia - blood | Kidney - metabolism | Ferric Compounds - pharmacokinetics | Chelating Agents - pharmacokinetics | Vascular Calcification - etiology | Phosphates - blood | Kidney - physiopathology | Chelating Agents - adverse effects | Disease Models, Animal | Sucrose - administration & dosage | Gastrointestinal Absorption | Risk Assessment | Vascular Calcification - blood | Rats | Sucrose - adverse effects | Vascular Calcification - prevention & control | Renal Insufficiency, Chronic - physiopathology | Renal Insufficiency, Chronic - blood | Animals | Hyperphosphatemia - etiology | Uremia - blood | Dogs | Hyperphosphatemia - drug therapy | Ferric Compounds - adverse effects | Hyperphosphatemia - physiopathology | Drug Combinations
Journal Article
Regulatory Toxicology and Pharmacology, ISSN 0273-2300, 02/2011, Volume 59, Issue 1, pp. 176 - 183
Journal Article
Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, 08/2019, Volume 125, Issue 2, pp. 133 - 141
Journal Article
Journal Article